Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma.
about
EGFR Signaling in Liver DiseasesThe Epidermal Growth Factor Receptor (EGFR) Inhibitor Gefitinib Reduces but Does Not Prevent Tumorigenesis in Chemical and Hormonal Induced Hepatocarcinogenesis Rat ModelsIn vivo photoacoustic tomography of EGFR overexpressed in hepatocellular carcinoma mouse xenograft.Effect of blocking IGF-I receptor on growth of human hepatocellular carcinoma cells.Oncolytic Virus-Based Immunotherapies for Hepatocellular Carcinoma.A systems biology-based classifier for hepatocellular carcinoma diagnosis.EGFR has a tumour-promoting role in liver macrophages during hepatocellular carcinoma formation.Peritumoral small ephrinA5 isoform level predicts the postoperative survival in hepatocellular carcinomaExploiting novel molecular targets in gastrointestinal cancers.Hepatitis C virus-mediated angiogenesis: molecular mechanisms and therapeutic strategies.Could HBx protein expression affect signal pathway inhibition by gefitinib or selumetinib, a MEK inhibitor, in hepatocellular carcinoma cell lines?Growth suppression of human hepatocellular carcinoma xenografts by a monoclonal antibody CH12 directed to epidermal growth factor receptor variant IIINovel therapeutic strategies for targeting liver cancer stem cells.The effects of a novel MEK inhibitor PD184161 on MEK-ERK signaling and growth in human liver cancer.Combined treatment with silibinin and either sorafenib or gefitinib enhances their growth-inhibiting effects in hepatocellular carcinoma cells.Cytosolic phospholipase A(2)α protects against Fas- but not LPS-induced liver injury.Comparison of Helicobacter bilis-Associated Protein Expression in Huh7 Cells Harbouring HCV Replicon and in Replicon-Cured CellsPrognosis of hepatocellular carcinoma expressing cytokeratin 19: comparison with other liver cancers.Prediction of liver injury induced by chemicals in human with a multiparametric assay on isolated mouse liver mitochondria.Gefitinib: an adverse effects profile.New molecular targets for hepatocellular carcinoma: the ErbB1 signaling system.New perspectives and strategy research biomarkers for hepatocellular carcinoma.Immunohistochemical markers associated with brain metastases in patients with nonsmall cell lung carcinomaCyclooxygenase-2 prevents fas-induced liver injury through up-regulation of epidermal growth factor receptor.Synergistic activity of vorinostat combined with gefitinib but not with sorafenib in mutant KRAS human non-small cell lung cancers and hepatocarcinoma.FOXM1 confers resistance to gefitinib in lung adenocarcinoma via a MET/AKT-dependent positive feedback loop.Targeted therapy of hepatocellular cancer.Tyrosine kinase inhibitors to treat liver cancer.Targeted therapy in gastrointestinal malignancies.Hepatic cancer stem cells and drug resistance: Relevance in targeted therapies for hepatocellular carcinoma.Translational medicine in hepatocellular carcinoma.Epidermal Growth Factor Receptor (EGFR) Crosstalks in Liver Cancer.Splicing factor hnRNP A2 activates the Ras-MAPK-ERK pathway by controlling A-Raf splicing in hepatocellular carcinoma developmentNovel mechanistic insights into ectodomain shedding of EGFR Ligands Amphiregulin and TGF-α: impact on gastrointestinal cancers driven by secondary bile acids.Synthesis, molecular docking and biological evaluation of glycyrrhizin analogs as anticancer agents targeting EGFR.Mechanisms involved in PGE2-induced transactivation of the epidermal growth factor receptor in MH1C1 hepatocarcinoma cells.EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib.Novel compounds with antiangiogenic and antiproliferative potency for growth control of testicular germ cell tumours.Tyrosine kinase of insulin-like growth factor receptor as target for novel treatment and prevention strategies of colorectal cancer.Preclinical activity of gefitinib in non-keratinizing nasopharyngeal carcinoma cell lines and biomarkers of response
P2860
Q26771265-4D452F8B-389C-4009-9845-899542F7F55DQ28820734-183DC3E4-8E40-4C6D-87C9-76AE763FCB4EQ30372076-E66E43EB-8CE1-49C1-8FDA-5D954BA00F6DQ33248446-8FFB1FF3-6EB5-44CB-A815-324B7F7532E0Q33635033-492FC5EB-2311-47A0-9554-BF29FEEF1841Q33987671-AA245349-BB20-491D-A941-70BAA5E19175Q34282375-79D63E76-A9D8-4293-9EC7-AE484FC2CFD8Q34364217-F896C35D-ABD8-4529-8DFA-B04C85EFF760Q34382777-687D441A-0EC4-4235-801A-287DB0596A3FQ34499002-B698FEC6-F216-4884-B328-B17306F23E17Q34539948-4C9D4715-0F03-4990-B4B1-3CF1E7AB55C6Q34568677-522F7CC1-1D37-4C90-B41A-CDFDF42BC8BDQ34940971-EEC144D6-FAE5-4A6E-9126-C4D2AB312BC5Q35081944-CFA424CF-9625-41A9-B7D1-8F5D1409517EQ35231826-1CBDA0D7-C0FB-41B6-BD08-88C74C7AC93EQ35566362-31B64867-DA3E-436B-801C-F4D9D810E494Q36147887-1C25D9C0-5B57-4467-811B-2D0A900BD309Q36233866-292B64BF-307C-4634-9975-56CB2317D803Q36247086-45C90138-DB54-4FBB-AD7B-3D5196FA94EBQ36446915-E0376064-511A-42CD-AEA6-0C716279663BQ36740642-0A6756CE-938D-4AC3-8522-22476CC24E28Q36883798-5E0614CE-D5A6-4550-82D2-AE38E920EEADQ37003601-FE151DEB-5A2C-456B-81F2-7E46E6CB6765Q37378968-F2A02C52-3C2C-431A-B13D-3D189AC64CFBQ37413127-9F9E074E-E103-4C0D-9213-8A87A9208454Q37644850-ED8D90B8-38D7-4CAC-8635-6FB1D11AFE80Q37674624-D2E2BBB1-E13B-479E-AFA4-FACEAD353224Q37686529-BA180845-B081-4507-83CD-6F96D5317CF5Q37702506-573DE281-0942-4293-ACED-28562E69C080Q37821305-211E1206-A2B8-408A-851F-A0AB9AF85629Q38008950-85F4D343-C25F-4815-9574-D7EB64521794Q38161361-D8EEB27E-85F7-44DE-B514-6A26E1BE0AFDQ38487106-3FF8CA7A-D438-4EE4-8361-8323FB2D90CDQ38615458-E3AAA717-6893-4EFD-9A6F-61D35A4EFDBFQ38992642-997BD517-6FC4-4EE3-B586-8DBE5EA5F8EBQ39281043-0D24F8AB-AAA8-48EC-BA9D-E012064160CAQ39362619-65AC7B1F-3306-4C7C-A1CD-4BAD748774C3Q39692519-4368427F-D0C3-486E-85EE-BBBB55E68308Q39769976-710A5604-11D1-4B62-B94B-8CEA9FCE488EQ39799281-6F575770-D646-4F44-996D-BF49FF56E03C
P2860
Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Targeting the epidermal growth ...... t of hepatocellular carcinoma.
@en
type
label
Targeting the epidermal growth ...... t of hepatocellular carcinoma.
@en
prefLabel
Targeting the epidermal growth ...... t of hepatocellular carcinoma.
@en
P2093
P1476
Targeting the epidermal growth ...... t of hepatocellular carcinoma.
@en
P2093
Alexander Huether
Andreas P Sutter
Detlef Schuppan
Hans Scherübl
Martin Zeitz
Michael Höpfner
P304
P356
10.1016/J.JHEP.2004.08.024
P577
2004-12-01T00:00:00Z